This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Stereotactic Body Radiation Therapy (SBRT) for Liver Oligometastases: outcomes and safety
Dejan Cazic
International Medical Centers Banja Luka
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1313-1128
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The aim of this study was to investigate adverse effects, progression free survival (PFS), one-year local control (LC) and one-year overall survival (OS) of patients with liver oligometastases treated with stereotactic body radiotherapy (SBRT), and whether there is a significant difference in these parameters in patients with primary colorectal cancer compared to other tumor localizations.
Methods: Patients were simulated using four-dimensional computed tomography (4DCT). Using volumetric modulated arc therapy (VMAT) technique, SBRT was performed on 16 patients with <3 liver metastases. The prescribed dose was 60 Gy in 8 fractions (BED 105 Gy). Cone beam CT (CBCT) was used for image guidance before each fraction with online correction.
Results: There were no adverse effects. Mean PFS for all patients, patients with primary colorectal cancer, and patients with primary non-colorectal cancer was 12.2 months (SD 8.3), 16.3 months (SD 7.9), 8.1 months (SD 6.8), respectively. There was a significant difference in the mean PFS for these two observed groups (p = 0.023). The one-year LC was 62.5%. Patients with primary colorectal cancer had the one-year LC of 87.5%, while the group of patients with primary non-colorectal cancer had the one-year LC of 37.5% (p = 0.014). The total one-year OS was 87.5%. In the group of patients with primary colorectal cancer, the one-year OS was 100%, while in the group of patients with primary non-colorectal cancer, the one-year OS was 75% (p = 0.147).
Conclusion: SBRT is a safe and effective method of treating liver oligometastases.
Keywords
SBRT, Liver, Oligometastases
Figure 1
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research
Stereotactic Body Radiation Therapy (SBRT) for Liver Oligometastases: outcomes and safety
Dejan Cazic
International Medical Centers Banja Luka
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1313-1128
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Jun, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The aim of this study was to investigate adverse effects, progression free survival (PFS), one-year local control (LC) and one-year overall survival (OS) of patients with liver oligometastases treated with stereotactic body radiotherapy (SBRT), and whether there is a significant difference in these parameters in patients with primary colorectal cancer compared to other tumor localizations.
Methods: Patients were simulated using four-dimensional computed tomography (4DCT). Using volumetric modulated arc therapy (VMAT) technique, SBRT was performed on 16 patients with <3 liver metastases. The prescribed dose was 60 Gy in 8 fractions (BED 105 Gy). Cone beam CT (CBCT) was used for image guidance before each fraction with online correction.
Results: There were no adverse effects. Mean PFS for all patients, patients with primary colorectal cancer, and patients with primary non-colorectal cancer was 12.2 months (SD 8.3), 16.3 months (SD 7.9), 8.1 months (SD 6.8), respectively. There was a significant difference in the mean PFS for these two observed groups (p = 0.023). The one-year LC was 62.5%. Patients with primary colorectal cancer had the one-year LC of 87.5%, while the group of patients with primary non-colorectal cancer had the one-year LC of 37.5% (p = 0.014). The total one-year OS was 87.5%. In the group of patients with primary colorectal cancer, the one-year OS was 100%, while in the group of patients with primary non-colorectal cancer, the one-year OS was 75% (p = 0.147).
Conclusion: SBRT is a safe and effective method of treating liver oligometastases.
Figure 1